By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

The alliance brings together Cellular Origins, a company focusing on applying robotics and other forms of automation to CGT ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

"Despite this decision of the Court of Justice, the European Commission continues to refuse to make the messages public," ...

The Immune Cell Engager Partnering & Investment Summit is here. As part of the game-changing Partnering & Investment Series, ...

A series of adverts for weight-loss services have been banned by the Advertising Standards Authority in the UK for promoting ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...